StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS stock opened at $0.03 on Tuesday. The firm has a market capitalization of $1.28 million, a P/E ratio of 0.00 and a beta of 1.68. The business’s 50-day moving average is $0.03 and its two-hundred day moving average is $0.04. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.78.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.